IL24 and neoplasm: Of note, the percentages of both MHC II+CD11c− APCs and DCs were substantially increased by ZD55-IL-24 therapy in local tumors, spleens, and distal tumors (Fig. 4E, J, L, P, U, Z), suggesting that the primary reason for the capacity of ZD55-IL-24 to induce systemic antitumor immunity in B16-bearing immunocompetent mouse model was attributed to the promotion of the recognition of original host immune system to tumor cells.